Table 3.

Laboratory markers of inflammation before and following tocilizumab therapy in patients that did and did not have improvement in respiratory parameters at day seven.

IV Group
	Responders (n = 34)			Non-responders (n = 31)
	Number	Before	After	Number	Before	After
C-reactive protein mg/L, mean ± SD	23	163 ± 95	47 ± 87a	20	228 ± 100	77 ± 102a
D-dimers ng/mL, mean ± SD	28	7116 ± 15,291	2216 ± 2432	23	11,629 ± 19,429	6963 ± 12,935
Ferritin ng/mL, mean ± SD	26	1064 ± 845	1010 ± 611	20	1376 ± 597	1450 ± 574
Interleukin-6 pg/mL, mean ± SD	11	109 ± 116	179 ± 259	9	465 ± 526	779 ± 748
Lactic acid dehydrogenase U/L, mean ± SD	20	585 ± 195	556 ± 223	17	874 ± 449	845 ± 363
Procalcitonin ng/mL, mean ± SD	17	8.32 ± 24.7	5.47 ± 14.3	14	3.94 ± 6.71	2.18 ± 3.58

SC Group
	Responders (n = 17)			Non-responders (n = 43)
	Number	Before	After	Number	Before	After
C-reactive protein mg/L, mean ± SD	13	165 ± 97.4	32.3 ± 28.8a	29	194 ± 106	79.5 ± 94.8a
D-dimers ng/mL, mean ± SD	14	6409 ± 16,199	3019 ± 4092	32	13,805 ± 19,371	7894 ± 13,555
Ferritin ng/mL, mean ± SD	13	1275 ± 601	1061 ± 630	31	1491 ± 766	1364 ± 617
Interleukin-6 pg/mL, mean ± SD	5	141 ± 236	563 ± 775	16	97.2 ± 86.1	738 ± 1011a
Lactic acid dehydrogenase U/L, mean ± SD	9	488 ± 226	480 ± 196	18	759 ± 328	705 ± 236
Procalcitonin ng/mL, mean ± SD	5	5.60 ± 10.4	2.12 ± 3.54	12	1.29 ± 1.52	8.88 ± 13.5

^aP≤0.05 comparing values between the two groups.